Read more

March 18, 2023
1 min read
Save

Jefferson Health’s Sidney Kimmel Cancer Center names vice president for cancer disparities

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Edith P. Mitchell, MD, MACP, FCCP, FRCP (London), has been named enterprise vice president for cancer disparities at Jefferson Health’s Sidney Kimmel Cancer Center.

In this new role, Mitchell will be responsible for developing and coordinating operations for cancer care disparities across Jefferson.

Graphic with quote from Andrew Chapman, DO

She will oversee a team focused on cancer care quality and cost-effectiveness, as well as patient-oriented outcomes. She also will focus on identifying and eliminating barriers to care, particularly those related to socioeconomic, racial or ethnic disparities and social determinants of health.

Edith P. Mitchell, MD, FACP, FCPP, FRCP
Edith P. Mitchell

“Dr. Mitchell has had an extraordinary career dedicated to eliminating health disparities affecting too many individuals and communities in the Philadelphia area and beyond,” Andrew Chapman, DO, director of Sidney Kimmel Cancer Center and executive vice president of oncology services at Jefferson Health, said in a press release. “Her work with community health providers has increased minority participation in clinical trials and she has brought cancer screening to neighborhoods lacking access to preventive care. Dr. Mitchell’s expertise and devotion to health equity is invaluable to the Sidney Kimmel Cancer Center in our commitment to deliver high-quality cancer care across the region.”

Mitchell also serves as director of Center to Eliminate Cancer Disparities and clinical professor of medicine and medical oncology at Jefferson Health’s Sidney Kimmel Cancer Center. She joined Jefferson in 1995.

Her research has focused on barriers to clinical trial participation, as well as novel drug evaluation and new treatment regimens for patients with breast cancer or gastrointestinal cancers.